Rate of antimicrobial use to treat multidrug-resistant organisms, by region
| Multidrug-resistant organism | Region; no. (%) of patients treated for multidrug-resistant organisms* | |||
|---|---|---|---|---|
| Total n = 1470 | Region | |||
| West n = 535 | Central n = 716 | Atlantic n = 219 | ||
| MRSA | 82 (5.6) | 51 (9.5) | 30 (4.2) | 1 (0.5) |
| MRCoNS | 33 (2.2) | 12 (2.2) | 18 (2.5) | 3 (1.4) |
| VRE | 10 (0.7) | 4 (0.7) | 6 (0.8) | 0 |
| ESBL-producing Enterobacteriaceae | 41 (2.8) | 22 (4.1) | 11 (1.5) | 8 (3.7) |
| 3-ceph | 60 (4.1) | 26 (4.9) | 19 (2.7) | 15 (6.8) |
| CRE | 5 (0.3) | 5 (0.9) | 0 | 0 |
| ESBL-NF | 22 (1.5) | 12 (2.2) | 9 (1.3) | 1 (0.5) |
| CR-NF | 25 (1.7) | 9 (1.7) | 13 (1.8) | 3 (1.4) |
| Other multidrug-resistant organism | 75 (5.1) | 45 (8.4) | 24 (3.4) | 6 (2.7) |
Note: 3-ceph = third-generation cephalosporin-resistant Enterobacterales, CRE = carbapenem-resistant Enterobacterales, CR-NF = carbapenem-resistant nonfermenter Gram-negative bacilli, ESBL = extended-spectrum β-lactamase, ESBL-NF = ESBL-producing nonfermenter gram-negative bacilli, MRCoNS = methicillin-resistant coagulase-negative staphylococci, MRSA = methicillin-resistant Staphylococcus aureus, VRE = vancomycin-resistant enterococci.
↵* The denominator for the percentages in this table is the number of patients receiving antimicrobials for targeted use.